Envista Reports First Quarter 2025 Results

Rhea-AI Summary

Envista Holdings (NYSE: NVST) reported Q1 2025 results with sales of $617 million and a modest core sales growth of 0.2% compared to Q1 2024. The company posted net income of $18 million, down from $24 million in the prior year, with adjusted EBITDA margin at 12.8%. EPS decreased to $0.10 from $0.14, while adjusted EPS came in at $0.24. Equipment & Consumables segment showed positive growth, while Specialty Products & Technologies experienced modest contraction due to VBP preparations in China. Operating cash flow was $0 million with negative free cash flow of ($5) million. The company repurchased 1.1 million shares for $19 million and maintained its 2025 guidance of 1-3% core sales growth and adjusted EBITDA margins of approximately 14%.

Positive

• Core sales increased 0.2% year-over-year
• Positive growth in Equipment & Consumables segment
• Growth in Nobel Biocare and Spark clear aligners
• Continued gross margin improvement in Spark
• Maintained full-year 2025 guidance
• Share repurchase of 1.1 million shares for $19 million

Negative

• Net income declined to $18M from $24M year-over-year
• EPS decreased to $0.10 from $0.14 year-over-year
• Operating cash flow dropped to $0M from $40M in Q1 2024
• Negative free cash flow of ($5M) compared to $29M in Q1 2024
• Contraction in Ortho business in China due to VBP preparations

Insights

Financial Analyst

Envista's Q1 shows declining profits and concerning cash flow deterioration, yet maintains full-year guidance indicating expected improvement ahead.

Envista's Q1 2025 results paint a picture of a company facing some near-term challenges while maintaining confidence in its full-year outlook. The company reported sales of $617 million with minimal core growth of just 0.2% year-over-year, indicating essentially flat performance.

The profitability metrics reveal a clear downward trend from the previous year. Net income fell 25% to $18 million from $24 million in Q1 2024, while adjusted EPS decreased to $0.24 from $0.26. The adjusted EBITDA margin of 12.8% was described as "consistent with expectations," suggesting the company had anticipated this performance level.

The most concerning element in this report is the dramatic deterioration in cash flow. Operating cash flow collapsed to $0 from $40 million in the comparable quarter, while free cash flow turned negative at ($5 million) compared to $29 million last year. This significant cash generation weakness could potentially constrain financial flexibility if the trend continues.

Business segment performance was mixed. Equipment & Consumables achieved positive growth, with the Consumables business offsetting continued softness in Diagnostics. Meanwhile, Specialty Products & Technologies experienced modest contraction, with growth in Nobel Biocare and Spark clear aligners unable to fully offset declines in the China Ortho business due to Volume-Based Procurement preparations.

Despite these challenges, management maintained its full-year 2025 guidance of 1-3% core sales growth, approximately 14% adjusted EBITDA margins, and adjusted EPS of $0.95-$1.05. This suggests leadership anticipates improved performance in subsequent quarters to offset the weak start to the year.

The company's continuation of its share repurchase program—buying back 1.1 million shares for approximately $19 million—indicates management's confidence in the company's valuation despite the current performance challenges.

BREA, Calif., May 1, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) today announced results for the quarter ended March 28, 2025.

"In the first quarter, Envista delivered results in line with our expectations building on the momentum established across the second half of 2024," said Paul Keel, CEO. "We continued to drive improvements across our three priority areas of growth, operations, and people. This was a solid start to the year, and we are maintaining our 2025 guidance."

Q1 2025 financial highlights:

• Sales were $617 million, with core sales increasing 0.2% over the first quarter of 2024.
• Net Income was $18 million and adjusted EBITDA margin was 12.8%, consistent with our expectations.
• Positive growth in Equipment & Consumables, as growth in our Consumables business more than offset continued softness in the Diagnostics market.
• Modest contraction in Specialty Products & Technologies, as positive growth in Nobel Biocare and Spark clear aligners was offset by contraction in Ortho in China due to VBP preparations.
• EPS of $0.10 and adjusted EPS of $0.24, ahead of our expectations.

Q1 2025 operational highlights:

• Growth: Positive growth in Consumables, Nobel Biocare, Spark, and also in Brackets & Wires outside China.
• Operations: Broad-based contributions from EBS, continued gross margin improvement in Spark, continued high customer service levels, good G&A productivity.
• People: Gains in employee engagement and retention, refreshed leadership team performing well.

Net Income, EPS, and EBITDA (in millions, except per share amounts):

	Three Months Ended
	March 28, 2025		March 29, 2024
Net Income	$                              18		$                              24
Adjusted Net Income	$                              42		$                              46
Diluted Earnings Per Share	$                           0.10		$                           0.14
Adjusted Diluted Earnings Per Share	$                           0.24		$                           0.26
Adjusted EBITDA	$                              79		$                              87

Cash flow:

Operating cash flow for the first quarter of 2025 was $0 million and free cash flow was ($5) million, compared to $40 million and $29 million in the first quarter of 2024, respectively. 

Share repurchases:

During the quarter ended March 28, 2025, we repurchased 1.1 million shares for approximately $19 million. At the end of the quarter, we had $231 million remaining repurchase capacity under our stock repurchase program.

Outlook:

The company is maintaining its guidance for the full year 2025, which continues to be:

• Core sales growth of 1% to 3%
• Adjusted EBITDA margins of approximately 14%
• Adjusted earnings per share ranging between $0.95 and $1.05

Please note, we do not provide forward-looking estimates on a GAAP basis as certain information is not available and cannot be reasonably estimated.

Envista will discuss its quarterly results and provide details on its outlook for 2025 during an investor conference call today starting at 2:00 P.M. PT. The call and an accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com, under the subheading "Events & Presentations." A replay of the webcast will be available in the same section of Envista's website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.

The conference call can be accessed by dialing 800-225-9448 within the U.S. or +1 203-518-9708 outside the U.S. a few minutes before 2:00 PM PT and referencing conference ID #3526593.  A replay of the conference call will be available shortly after the conclusion of the call. You can access the replay dial-in information on the "Investors" section of Envista's website under the subheading "Events & Presentations." Presentation materials relating to Envista's results have been posted to the "Investors" section of Envista's website under the subheading "Quarterly Earnings."

ABOUT ENVISTA

Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr united by a shared purpose: to partner with professionals to improve lives. Envista helps its customers deliver the best possible patient care through industry-leading dental consumables, solutions, technology, and services. Our comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers a wide range of dentists' clinical needs for diagnosing, treating, and preventing dental conditions as well as improving the aesthetics of the human smile. With a foundation comprised of the proven Envista Business System (EBS) methodology, an experienced leadership team, and a strong culture grounded in continuous improvement, commitment to innovation, and deep customer focus, Envista is well equipped to meet the end-to-end needs of dental professionals worldwide. Envista is one of the largest global dental products companies, with significant market positions in some of the most attractive segments of the dental products industry. For more information, please visit www.envistaco.com.

NON-GAAP MEASURES

All "Adjusted" amounts including core sales growth and free cash flow are non-GAAP items. Calculations of these measures, the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these non-GAAP measures are included in the attached supplemental schedules. We do not reconcile forward looking non-GAAP measures to the comparable GAAP measures because of the inherent difficulty in predicting and estimating the future impact and timing of currency translation, acquisitions, discontinued products, and any other potential adjustments which would be reflected in any forecasted GAAP measure.

FORWARD-LOOKING STATEMENTS

Certain statements in this press release are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, the conditions in the U.S. and global economy, the impact of inflation and increasing interest rates, slower economic growth or recession, international economic, political, legal, compliance and business factors, the markets served by us and the financial markets, the impact of our debt obligations on our operations and liquidity, developments and uncertainties in trade policies and regulations including tariffs or other impositions on imported goods, contractions or growth rates and cyclicality of markets we serve, risks relating to product manufacturing, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole or limited sources of supply, disruptions relating to war, terrorism, climate change, widespread protests and civil unrest, man-made and natural disasters, public health issues and other events, security breaches or other disruptions of our information technology systems or violations of data privacy laws, security breaches or other disruptions affecting our external information technology contractors, vendors or other service providers, fluctuations in inventory of our distributors and customers, loss of a key distributor, our relationships with and the performance of our channel partners, competition, our ability to develop and successfully market new products and services, our ability to attract, develop and retain our key personnel, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, penalties associated with any off-label marketing of our products, modifications to our products that require new marketing clearances or authorizations, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions, contingent liabilities relating to acquisitions, investments and divestitures, our ability to adequately protect our intellectual property, the impact of our restructuring activities on our ability to grow, risks relating to impairment charges for our goodwill and intangible assets, changes in accounting standards and subjective assumptions, estimates and judgment by management, currency exchange rates, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, risks relating to product, service or software defects, the impact of regulation on demand for our products and services, and labor matters. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our Annual Report on Form 10-K for fiscal year 2024 and our Quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date of this press release and except to the extent required by applicable law, we do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.       

CONTACT
Jim Gustafson
Vice President, Investor Relations
Envista Holdings Corporation
200 S. Kraemer Blvd., Building E
Brea, CA 92821
IR@envistaco.com

 

ENVISTA HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
($ and shares in millions, except per share amounts)
	Three Months Ended
	March 28, 2025		March 29, 2024
Sales	$                  616.9		$                  623.6
Cost of sales	280.9		267.3
Gross profit	336.0		356.3
Operating expenses:
Selling, general and administrative	271.7		284.9
Research and development	25.3		23.3
Operating profit	39.0		48.1
Nonoperating (expense) income:
Other (expense) income, net	(0.7)		0.1
Interest expense, net	(9.3)		(12.9)
Income before income taxes	29.0		35.3
Income tax expense	11.0		11.7
Net income	$                     18.0		$                    23.6
Earnings per share:
Earnings - basic	$                     0.10		$                    0.14
Earnings - diluted	$                     0.10		$                    0.14
Average common stock and common equivalent shares outstanding:
Basic	172.4		171.9
Diluted	173.6		173.4

 

ENVISTA HOLDINGS CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)
($ in millions, except share amounts)
	As of
	March 28, 2025		December 31, 2024
ASSETS
Current assets:
Cash and cash equivalents	$                 1,077.3		$             1,069.1
Trade accounts receivable, less allowance for credit losses of $26.6 and $26.6, respectively	393.1		363.0
Inventories, net	261.3		241.0
Prepaid expenses and other current assets	118.0		115.2
Total current assets	1,849.7		1,788.3
Property, plant and equipment, net	279.7		277.0
Operating lease right-of-use assets	138.7		142.8
Other long-term assets	244.7		230.6
Goodwill	2,303.4		2,261.9
Other intangible assets, net	650.2		649.9
Total assets	$                 5,466.4		$             5,350.5
LIABILITIES AND EQUITY
Current liabilities:
Short-term debt	$                    116.2		$                 116.0
Trade accounts payable	163.5		174.6
Accrued expenses and other liabilities	558.8		553.6
Operating lease liabilities	34.8		34.5
Total current liabilities	873.3		878.7
Operating lease liabilities	113.7		118.9
Other long-term liabilities	147.5		139.8
Long-term debt	1,295.8		1,278.3
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.01 par value, 15.0 million shares authorized; no shares issued or outstanding at March 28, 2025 and December 31, 2024	—		—
Common stock, $0.01 par value, 500.0 million shares authorized; 174.9 million shares issued and 171.5 million shares outstanding at March 28, 2025; 174.2 million shares issued and 172.2 million shares outstanding at December 31, 2024	1.7		1.7
Treasury stock at cost; 3.4 million shares and 2.0 million shares at March 28, 2025 and December 31, 2024, respectively	(73.1)		(50.5)
Additional paid-in capital	3,850.0		3,842.1
Accumulated deficit	(469.4)		(487.4)
Accumulated other comprehensive loss	(273.1)		(371.1)
Total stockholders' equity	3,036.1		2,934.8
Total liabilities and stockholders' equity	$                 5,466.4		$             5,350.5

 

ENVISTA HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
($ in millions)
	Three Months Ended
	March 28, 2025		March 29, 2024
Cash flows from operating activities:
Net income	$                      18.0		$                       23.6
Noncash items:
Depreciation	9.1		9.5
Amortization	18.8		22.6
Allowance for credit losses	1.3		4.5
Stock-based compensation expense	7.1		11.0
Loss on investments in rabbi trust, net	0.6		—
Restructuring charges	0.2		(0.2)
Fixed assets impairments and other charges	—		0.8
Non-cash operating lease costs	8.4		7.3
Amortization of debt discount and issuance costs	1.1		1.2
Change in trade accounts receivable	(21.3)		(16.3)
Change in inventories	(10.1)		(12.2)
Change in trade accounts payable	(15.1)		(2.7)
Change in prepaid expenses and other assets	(7.8)		(3.8)
Change in accrued expenses and other liabilities	0.8		4.3
Change in operating lease liabilities	(10.8)		(9.3)
Net cash provided by operating activities	0.3		40.3
Cash flows from investing activities:
Payments for additions to property, plant and equipment	(5.9)		(11.0)
Purchases of investments held in rabbi trust	(0.7)		—
Proceeds from sale of investments held in rabbi trust	0.7		—
Proceeds from sales of property, plant and equipment	0.5		—
All other investing activities, net	(3.4)		0.3
Net cash used in investing activities	(8.8)		(10.7)
Cash flows from financing activities:
Proceeds from stock option exercises	0.8		1.3
Cash paid for treasury stock	(14.6)		—
Tax withholding payment related to net settlement of equity awards	(3.8)		(3.3)
All other financing activities	—		(0.6)
Net cash used in financing activities	(17.6)		(2.6)
Effect of exchange rate changes on cash and cash equivalents	34.3		(18.5)
Net change in cash and cash equivalents	8.2		8.5
Beginning balance of cash and cash equivalents	1,069.1		940.0
Ending balance of cash and cash equivalents	$                1,077.3		$                    948.5

 

ENVISTA HOLDINGS CORPORATION
SUMMARY OF FINANCIAL METRICS (Unaudited)
($ in millions, except per share amounts)
	GAAP
	Three Months Ended
	March 28, 2025		March 29, 2024
Gross Profit	$                   336.0		$                   356.3
Operating Profit	$                     39.0		$                     48.1
Net Income	$                     18.0		$                     23.6
Diluted Earnings Per Share	$                     0.10		$                     0.14
Operating Cash Flow	$                       0.3		$                     40.3
	NON-GAAP *
	Three Months Ended
	March 28, 2025		March 29, 2024
Adjusted Gross Profit	$                    338.3		$                   358.0
Adjusted Operating Profit	$                      70.6		$                     77.6
Adjusted Net Income	$                      41.5		$                     45.8
Adjusted Diluted EPS	$                      0.24		$                     0.26
Adjusted EBITDA	$                      79.0		$                     87.2
Free Cash Flow	$                       (5.1)		$                     29.3

* For information on non-GAAP measures see "Reconciliation of GAAP to Non-GAAP Financial Measures" below. Also see the accompanying "Notes to Reconciliation of GAAP to Non-GAAP Financial Measures."

 

ENVISTA HOLDINGS CORPORATION
SEGMENT INFORMATION (Unaudited)
($ in millions)
	Three Months Ended
	March 28, 2025		March 29, 2024
Sales
Specialty Products & Technologies	$                  400.3		$                  408.7
Equipment & Consumables	216.6		214.9
Total	$                  616.9		$                  623.6
Operating Profit (Loss)
Specialty Products & Technologies	$                    37.6		$                    44.2
Equipment & Consumables	31.9		35.6
Other	(30.5)		(31.7)
Total	$                    39.0		$                    48.1
Operating Margins
Specialty Products & Technologies	9.4 %		10.8 %
Equipment & Consumables	14.7 %		16.6 %
Total	6.3 %		7.7 %

 

ENVISTA HOLDINGS CORPORATION
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (UNAUDITED)
($ in millions, except per share amounts)
Adjusted Gross Profit and Adjusted Gross Margin
	Three Months Ended
	March 28, 2025		March 29, 2024
Gross Profit	$              336.0		$              356.3
Restructuring costs and asset impairments A	1.9		1.7
Fair value adjustment of acquisition-related inventory B	0.4		—
Adjusted Gross Profit	$              338.3		358.0
Gross Margin (Gross Profit / Sales)	54.5 %		57.1 %
Adjusted Gross Margin (Adjusted Gross Profit / Sales)	54.8 %		57.4 %
Adjusted Operating Profit
	Three Months Ended
	March 28, 2025		March 29, 2024
Consolidated
Operating Profit	$                39.0		$                48.1
Amortization of acquisition-related and other intangible assets	18.8		22.6
Restructuring costs and asset impairments A	11.4		6.9
Fair value adjustment of acquisition-related inventory B	0.4		—
Litigation settlement C	0.8		—
Acquisition related expenses D	0.2		—
Adjusted Operating Profit	$                70.6		$                77.6
Adjusted Operating Profit as a % of Sales	11.4 %		12.4 %
Specialty Products & Technologies
Operating Profit	$                37.6		$                44.2
Amortization of acquisition-related and other intangible assets	14.6		14.4
Restructuring costs and asset impairments A	4.2		3.3
Adjusted Operating Profit	$                56.4		$                61.9
Adjusted Operating Profit as a % of Sales	14.1 %		15.1 %
Equipment & Consumables
Operating Profit	$                31.9		$                35.6
Amortization of acquisition-related and other intangible assets	4.2		8.2
Restructuring costs and asset impairments A	2.3		2.8
Litigation settlement C	0.8		—
Adjusted Operating Profit	$                39.2		$                46.6
Adjusted Operating Profit as a % of Sales	18.1 %		21.7 %
See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

 

Adjusted Net Income
	Three Months Ended
	March 28, 2025		March 29, 2024
Net Income	$                    18.0		$                    23.6
Amortization of acquisition-related and other intangible assets	18.8		22.6
Restructuring costs and asset impairments A	11.4		6.9
Fair value adjustment of acquisition-related inventory B	0.4		—
Litigation settlement C	0.8		—
Acquisition related expenses D	0.2		—
Tax effect of adjustments reflected above E	(8.8)		(7.6)
Discrete tax adjustments and other tax-related adjustments F	0.7		0.3
Adjusted Net Income	$                    41.5		$                    45.8
Adjusted Diluted Earnings Per Share
	Three Months Ended
	March 28, 2025		March 29, 2024
Diluted Earnings	$                    0.10		$                    0.14
Amortization of acquisition-related and other intangible assets	0.11		0.13
Restructuring costs and asset impairments A	0.07		0.04
Fair value adjustment of acquisition-related inventory B	—		—
Litigation settlement C	0.01		—
Acquisition related expenses D	—		—
Tax effect of adjustments reflected above E	(0.05)		(0.05)
Discrete tax adjustments and other tax-related adjustments F	—		—
Adjusted Diluted Earnings Per Share	$                    0.24		$                    0.26
Adjusted EBITDA
	Three Months Ended
	March 28, 2025		March 29, 2024
Net Income	$                18.0		$                23.6
Interest expense, net	9.3		12.9
Income tax expense	11.0		11.7
Depreciation	9.1		9.5
Amortization of acquisition-related and other intangible assets	18.8		22.6
Restructuring costs and asset impairments A	11.4		6.9
Fair value adjustment of acquisition-related inventory B	0.4		—
Litigation settlement C	0.8		—
Acquisition related expenses D	0.2		—
Adjusted EBITDA	$                79.0		$                87.2
Adjusted EBITDA as a % of Sales	12.8 %		14.0 %
See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

 

Core Sales Growth 1
Consolidated	% Change Three Month Period Ended March 28, 2025 vs. Comparable 2024 Period
Total sales growth	(1.1) %
Plus the impact of:
Acquisitions	(0.1) %
Currency exchange rates	1.4 %
Core sales growth	0.2 %
Specialty Products & Technologies
Total sales growth	(2.1) %
Plus the impact of:
Acquisitions	(0.1) %
Currency exchange rates	1.5 %
Core sales growth	(0.7) %
Equipment & Consumables
Total sales growth	0.8 %
Plus the impact of:
Currency exchange rates	0.9 %
Core sales growth	1.7 %

1

We use the term "core sales" to refer to GAAP revenue excluding  (1) sales from acquired businesses recorded prior to the first anniversary of the acquisition ("acquisitions"), (2) sales from discontinued products and (3) the impact of currency translation. Sales from discontinued products includes major brands or products that Envista has made the decision to discontinue as part of a portfolio restructuring. Discontinued brands or products consist of those which Envista (1) is no longer manufacturing, (2) is no longer investing in the research or development of, and (3) expects to discontinue all significant sales within one year from the decision date to discontinue. The portion of sales attributable to discontinued brands or products is calculated as the net decline of the applicable discontinued brand or product from period-to-period. The portion of GAAP revenue attributable to currency exchange rates is calculated as the difference between (a) the period-to-period change in sales and (b) the period-to-period change in sales after applying current period foreign exchange rates to the prior year period. We use the term "core sales growth" to refer to the measure of comparing current period core sales with the corresponding period of the prior year.

 

Reconciliation of Operating Cash Flows to Free Cash Flow
	Three Months Ended
	March 28, 2025		March 29, 2024
Net Operating Cash Provided by Operating Activities	$                      0.3		$                    40.3
Less: payments for additions to property, plant and equipment (capital expenditures)	(5.9)		(11.0)
Plus: proceeds from sales of property, plant and equipment	0.5		—
Free Cash Flow	$                    (5.1)		$                    29.3
See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

ENVISTA HOLDINGS CORPORATION
NOTES TO RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (UNAUDITED)

^A We exclude impairment of certain long-lived assets, executive transition costs, and cost incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size, strategic nature and planning requirements) from the ongoing productivity improvements, that result from application of the Envista Business System. These costs are incremental to the operating activities that arise in the ordinary course of our business and we believe are not indicative of Envista's ongoing operating costs in a given period. 

^B Represents the fair value adjustment related to inventory acquired in connection with acquisitions.

^C Represents the settlement of certain litigation matters.

^D Represents acquisition related transaction expenses and integration costs with respect to business combinations.

^E This line item reflects the aggregate tax effect of all pretax adjustments reflected in the preceding line items of the table using each adjustment's applicable tax rate, including the effect of interim tax accounting requirements of Accounting Standards Codification Topic 740 Income Taxes.

^F The discrete tax matters relate primarily to excess tax benefits from stock-based compensation, changes in estimates associated with prior period uncertain tax positions and audit settlements, tax benefits resulting from a change in law, and changes in determination of realization of certain deferred tax assets.

Statement Regarding Non-GAAP Measures

Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to investors by offering additional ways of viewing Envista Holdings Corporation's ("Envista" or the "Company") results that, when reconciled to the corresponding GAAP measure, help our investors to:

• with respect to Adjusted Gross Profit, Adjusted Operating Profit, Adjusted Net Income, Adjusted Diluted Earnings Per Share and Adjusted EBITDA, understand the long-term profitability trends of Envista's business and compare Envista's profitability to prior and future periods and to Envista's peers;
• with respect to Core Sales, identify underlying growth trends in Envista's business and compare Envista's revenue performance with prior and future periods and to Envista's peers;
• with respect to Adjusted EBITDA, help investors understand operational factors associated with Envista's financial performance because it excludes the following from consideration: interest, taxes, depreciation, amortization, and infrequent or unusual losses or gains such as goodwill impairment charges or nonrecurring and restructuring charges. Management uses Adjusted EBITDA, as a supplemental measure for assessing operating performance in conjunction with related GAAP amounts. In addition, Adjusted EBITDA is used in connection with operating decisions, strategic planning, annual budgeting, evaluating Company performance and comparing operating results with historical periods and with industry peer companies; and
• with respect to Free Cash Flow (the "FCF Measure"), understand Envista's ability to generate cash without external financings, in order to invest and grow its business through acquisitions and other strategic opportunities. A limitation of free cash flow is that it does not take into account the Company's debt service requirements and other non-discretionary expenditures, and as a result the entire Free Cash Flow amount is not necessarily available for discretionary expenditures.

Management uses these non-GAAP measures to evaluate the Company's operating and financial performance.

The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:

• With respect to Adjusted Gross Profit, Adjusted Operating Profit, Adjusted Net Income, Adjusted Diluted Earnings Per Share and Adjusted EBITDA:
  • We exclude amortization of acquisition-related and other intangible assets because the amount and timing of such charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate. While we have a history of significant acquisition activity, we do not acquire businesses on a predictable cycle, and the amount of an acquisition's purchase price allocated to intangible assets and related amortization term are unique to each acquisition and can vary significantly from acquisition to acquisition. Exclusion of this amortization expense facilitates more consistent comparisons of operating results over time between our newly acquired and long-held businesses, and with both acquisitive and non-acquisitive peer companies. We believe, however, that it is important for investors to understand that such intangible assets contribute to revenue generation and that intangible asset amortization related to past acquisitions will recur in future periods until such intangible assets have been fully amortized.
  • With respect to the other items excluded from Adjusted Gross Profit, Adjusted Net Income, Adjusted Operating Profit, Adjusted Diluted Earnings Per Share and Adjusted EBITDA, we exclude these items because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to Envista's commercial performance during the period and/or we believe that such items may obscure underlying business trends and make comparisons of long-term performance difficult.
• With respect to core sales, we exclude (1) the effect of acquisitions and divested product lines because the timing, size, number and nature of such transactions can vary significantly from period-to-period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult, (2) sales from discontinued products because discontinued products do not have a continuing contribution to operations and management believes that excluding such items provides investors with a means of evaluating our on-going operations and facilitates comparisons to our peers, and (3) the impact of currency translation because it is not under management's control, is subject to volatility and can obscure underlying business trends.
• With respect to the FCF Measure, we adjust for payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to arrive at the amount of operating cash flow for the period that remains after accounting for the Company's capital expenditure requirements.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/envista-reports-first-quarter-2025-results-302444426.html

SOURCE Envista Holdings Corporation

FAQ

What were Envista's (NVST) Q1 2025 earnings per share?

Envista reported Q1 2025 EPS of $0.10 and adjusted EPS of $0.24, compared to $0.14 and $0.26 respectively in Q1 2024.

What is Envista's (NVST) revenue guidance for 2025?

Envista maintained its 2025 guidance with core sales growth of 1% to 3% and adjusted EBITDA margins of approximately 14%.

How much did Envista (NVST) spend on share repurchases in Q1 2025?

Envista repurchased 1.1 million shares for approximately $19 million in Q1 2025, with $231 million remaining in their repurchase program.

What was Envista's (NVST) Q1 2025 revenue?

Envista reported Q1 2025 sales of $617 million, with core sales increasing 0.2% compared to Q1 2024.

What segments showed growth for Envista (NVST) in Q1 2025?

Equipment & Consumables showed positive growth, along with Nobel Biocare and Spark clear aligners, while Specialty Products & Technologies experienced modest contraction due to China market conditions.